Objectives: There are some studies that evaluated changes of bone marrow density (BMD) and re-fracture after zoledronic acid injection. However, there is no study that showed about the fracture on all of the body, fracture healing, and improvement of clinical symptom after zoledronic acid injection. In this study, authors evaluated the 1 year BMD change, changes of lumbar pain in lumbar spine fractures, effects on fracture healing, re-fracture and additional fracture on other site after zoledronic acid injection in patients with spine and non-spine fracture.
Methods: Patients who had lower than −2.5 (T-score) at BMD from January 2011 to June 2012 in our hospital were evaluated. Among them, patients who had spine fracture and/or non-spine fracture were enrolled. Zoledronic acid was injected in 3 days after fracture. BMD was checked 1 year later after injection. Furthermore, changes of lumbar pain in lumbar spine fractures was evaluated every weeks, effects on fracture healing, re-fracture and additional fracture on other site also were evaluated for this study.
Results: Spine fracture group (n=97) and non-spine fracture group (n=31) showed significant increasing of BMD (P<0.05). Visual analogue scale (VAS) for lumbar pain after spine fracture was reduced from 6.6±2.2 before zoledronic acid injection to 4.2±1.1 after injection. There was no delayed union or non-union after non-spine fractures. However, new fractures developed in three cases (2.34%); two spine fractures, one distal radius fracture.
Conclusions: There are increasing of BMD, relief of lumbar pain, no disruption to fracture healing after injection of zoledronic acid for osteoporotic patients who has spine fracture or non-spine fracture is good treatment option.
14 May 2016 - 17 May 2016